MMP9 and cancer: The four-biomarker panel comprising S100A7, CSTA, MMP9 and SERPINA 10 predicted early-stage cancer with AUC 0.83 (0.74–0.92) (Fig. 3b) while the equivalent ten-marker panel additionally incorporating RTN4, LAMP2, WDR1, KRT13, ALDH2 and ILF3 predicted early-stage endometrial cancer with AUC of 0.90 (0.84–0.96) (Fig. 3b and Table S2).